Myriad Genetics (MYGN) EPS (Weighted Average and Diluted): 2009-2025
Historic EPS (Weighted Average and Diluted) for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -$0.29.
- Myriad Genetics' EPS (Weighted Average and Diluted) fell 20.83% to -$0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.33, marking a year-over-year decrease of 238.37%. This contributed to the annual value of -$1.41 for FY2024, which is 55.66% up from last year.
- According to the latest figures from Q3 2025, Myriad Genetics' EPS (Weighted Average and Diluted) is -$0.29, which was up 91.88% from -$3.57 recorded in Q2 2025.
- Myriad Genetics' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.30 during Q3 2021, with a 5-year trough of -$3.57 in Q2 2025.
- In the last 3 years, Myriad Genetics' EPS (Weighted Average and Diluted) had a median value of -$0.41 in 2024 and averaged -$0.77.
- In the last 5 years, Myriad Genetics' EPS (Weighted Average and Diluted) spiked by 250.00% in 2021 and then slumped by 770.73% in 2025.
- Myriad Genetics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.10 in 2021, then crashed by 420.00% to -$0.52 in 2022, then surged by 34.62% to -$0.34 in 2023, then slumped by 38.24% to -$0.47 in 2024, then declined by 20.83% to -$0.29 in 2025.
- Its last three reported values are -$0.29 in Q3 2025, -$3.57 for Q2 2025, and -$0.00 during Q1 2025.